-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
preface
The 2022 Annual Meeting of the European Society of Oncology (ESMO) will be held
Merkel cell carcinoma is an aggressive cutaneous malignancy associated
This multicenter Phase 2 randomized study included patients with unresectable, recurrent, or metastatic Merkel cell carcinoma who received navulijumab 240 mg IV q2 wks + ipilimumab 1 mg/kg IV q6 wks (Arm A) or navuliumab 240 mg IV q2 wks + ipicumab 1 mg/kg IV q6 wks + SBRT on a 1:1 scale (24Gy, group B)
A total of 50 patients (24 without ICI and 26 had received ICI), 25 received navuliyuzumab + ipicizumab, and 25 patients received navuliyumab + ipicimumab + SBRT (median follow-up time of 14.
The ORR is 100% (95% CI, 82% to 100%) in patients with ICI and a complete response (CR) rate is 41%.
The study showed that the first-line treatment of patients with advanced Merkel cell carcinoma with navulijumab + ipicumab reached 100%, the response was long-lasting and safe, and it also showed clinical activity
References:
1.
S.
Kim,et al.
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.
2022 ESMO.
Abstract LBA42.
Editing/Typography: Jiang Zhou
Execution: Small garden